However, approximately 50% of ccRCC cases exhibit resistance to HIF2-α inhibitor treatment (6), underscoring the importance of identifying additional therapeutic vulnerabilities for ccRCC. Here, EPAS1 is linked to nonpapillary renal cell carcinoma.